Cosmo Pharmaceuticals NV (CHIX:COPNZ) Total Inventories : CHF13.1 Mil (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Total Inventories?

Cosmo Pharmaceuticals NV's total inventories for the quarter that ended in Jun. 2023 was CHF13.1 Mil. Cosmo Pharmaceuticals NV's average total inventories from the quarter that ended in Dec. 2022 to the quarter that ended in Jun. 2023 was CHF12.2 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cosmo Pharmaceuticals NV's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was CHF-3.32.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cosmo Pharmaceuticals NV's Days Inventory for the six months ended in Jun. 2023 was 121.29.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cosmo Pharmaceuticals NV's Inventory Turnover for the quarter that ended in Jun. 2023 was 1.50.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cosmo Pharmaceuticals NV's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.29.

Cosmo Pharmaceuticals NV Total Inventories Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Total Inventories Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

4.44

6.71

6.17

13.65

11.35

Cosmo Pharmaceuticals NV Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Inventories	Get a 7-Day Free Trial															10.86	13.65	15.39	11.35	13.12

Cosmo Pharmaceuticals NV Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Cosmo Pharmaceuticals NV (CHIX:COPNz) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cosmo Pharmaceuticals NV's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

	Net-Net Working Capital Per Share (Q: Jun. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(216.641	+	0.75 * 28.55	+	0.5 * 13.122	-	291.345
-	0	-	6.693)	/	16.076
=	-3.32

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cosmo Pharmaceuticals NV's Days Inventory for the six months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	12.2345	/	18.409	*	365 / 2
	=	121.29

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cosmo Pharmaceuticals NV's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	18.409	/	12.2345
	=	1.50

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cosmo Pharmaceuticals NV's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	12.2345	/	42.592
	=	0.29

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Cosmo Pharmaceuticals NV Total Inventories Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

CMOPF:USA C43:Germany COPN:Switzerland

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines